About Michael Weiss
Michael Weiss is an executive vice chairman at Fortress Biotech.
Form D filings name Michael Weiss as a director at Urica Therapeutics.
Michael Weiss reports to the SEC as a director, officer or major shareholder of 10 public companies, including TG Therapeutics (TGTX), Checkpoint Therapeutics (CKPT) and Mustang Bio (MBIO).
Michael Weiss first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name Michael Weiss in the role, so the role may have started earlier or lasted longer.
FI
Fortress Biotech, Inc.
Executive Vice Chairman
2013 – 2026 · Public company (FBIO)
TI
TG Therapeutics, Inc.
CEO and director
2012 – 2026 · Public company (TGTX)
CI
Checkpoint Therapeutics, Inc.
Exec. Chairman of the Board
2016 – 2025 · Public company (CKPT)
MI
Mustang Bio, Inc.
Exec. Chairman of the Board
2017 – 2023 · Public company (MBIO)
AI
Avenue Therapeutics, Inc.
Director
2017 – 2018 · Public company (ATXI)
NC
National Holdings Corp.
Director and 10% owner
2010 – 2016 · Public company (NHLD)
OC
Origo Acquisition Corp
Co-Chairman of the Board
2014 · Public company (OACQ)
KI
Keryx Biopharmaceuticals Inc.
Chief Executive Officer and director
2006 – 2010 · Public company (KERX)
AL
Arden Sage Triton Fund LLC
Director
2009 · Public company
XL
XTL Biopharmaceuticals Ltd.
Director
2008 · Public company (XTLB)
Key Colleagues at Startups
The people Michael Weiss works with at each company, as listed on that company's latest Form D.
Urica Therapeutics, Inc. · Form D, Jan 5, 2023
RZ
Raymond Zheng
Executive officer and director
JD
Jay Kranzler, M.D., Ph.D.
Executive officer and director
VD
Vibeke Strand, M.D.
Director
LD
Lindsay Rosenwald, M.D.
Director